Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
September 29, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
Medicare product coverage strategy
Proper planning for product pricing
Preparing comparative effectiveness data
Working with payer expectations
Data that should be in place for partnering or acquisition deals
Panelists:
Judith A. Waltz, Partner, Foley & Lardner LLP
Anita Chawla, Ph.D., Vice President, Analysis Group
Related Insights
June 27, 2025
Foley Viewpoints
The CFTC Is Shaking Up Sports Betting's Legal Future
What is gaming? In recent months, this has been the question at the intersection of the investing and betting industries. On Sept. 6, 2024, in the KalshiEX LLC v. Commodity Futures Trading Commission decision, the U.S. District Court for the District of Columbia weighed in, ruling that predicting the winner of a political election does not fall within the scope of "gaming," as the term is defined in the Commodity Exchange Act.
June 26, 2025
Energy Current
EPA Signals Approval of Texas’ Class VI Injection Well Primacy: Streamlining Carbon Capture and Climate Action
In a significant move for environmental policy and energy innovation, the U.S. Environmental Protection Agency (EPA) has proposed to…
June 26, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…